Azora Therapeutics (AZR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q2 FY2026, filed Oct 21, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AZR SEC filings page.
This page shows Azora Therapeutics, Inc. (AZR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Azora Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Azora Therapeutics, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
Azora Therapeutics, Inc. reported a net loss of $8.0M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Azora Therapeutics, Inc. reported a net loss of $52.0M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Azora Therapeutics, Inc. held $28.7M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Azora Therapeutics, Inc. invested $440K in research and development in Q2 2026. This represents a decrease of 39.9% from the same quarter a year earlier. Against the prior quarter it is up 1.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
AZR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $440K-39.9% | $433K-42.1% | $620K-15.2% | $521K-49.5% | $732K-27.7% | $747K+64.4% | $731K | $1.0M+398.1% |
| SG&A Expenses | $5.4M+369.6% | $1.6M+3.2% | $1.3M+4.7% | $1.2M+5.4% | $1.1M-9.8% | $1.5M+9.3% | $1.2M+2.7% | $1.2M+2.5% |
| Operating Income | -$52.0Mn/m | -$2.0Mn/m | -$1.9Mn/m | -$1.8Mn/m | -$1.9Mn/m | -$2.3Mn/m | -$1.9Mn/m | -$2.2Mn/m |
| Net Income | -$52.0Mn/m | -$2.0Mn/m | -$2.0Mn/m | -$1.8Mn/m | -$2.0Mn/m | -$2.2Mn/m | -$2.1Mn/m | -$2.2Mn/m |
| EPS (Basic) | -$11.25 | -$1.48 | N/A | -$0.08 | -$4.61 | -$8.52 | -$0.15 | -$0.38 |
| EPS (Diluted) | -$11.25 | -$1.48 | N/A | -$0.08 | -$4.61 | -$8.52 | -$0.15 | -$0.38 |
| Diluted Shares (Avg) | 5M | 1M | N/A | 22M | 424,908 | 261,590 | N/A | 6M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
AZR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $29.1M+327.7% | $5.2M+51.5% | $6.7M+32.3% | $5.7M-15.7% | $6.8M+37.4% | $3.5M | $5.0M+6.5% | $6.7M+134.1% |
| Current Assets | $28.8M+374.5% | $4.8M+82.7% | $6.2M+52.3% | $5.0M-10.8% | $6.1M+59.0% | $2.6M | $4.1M+26.9% | $5.6M+394.8% |
| Cash & Equivalents | $28.7M+385.4% | $4.6M+93.8% | $5.9M+56.8% | $4.6M-11.5% | $5.9M+79.9% | $2.4M-52.9% | $3.8M+32.7% | $5.2M+1547.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $67.5M+5471.0% | $1.5M+14.0% | $1.4M+43.2% | $1.2M+39.3% | $1.2M+80.2% | $1.3M | $976K+49.4% | $829K+57.0% |
| Current Liabilities | $5.1M+322.9% | $1.5M+14.0% | $1.4M+43.2% | $1.2M+39.3% | $1.2M+80.2% | $1.3M | $976K+49.4% | $829K+57.0% |
| Non-Current Liabilities | $62.3Mn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0n/m | $0n/m |
| Total Equity | -$38.4M-786.5% | $3.7M+74.8% | $5.3M+29.7% | $4.5M-23.4% | $5.6M+30.7% | $2.1M-65.3% | $4.1M-0.4% | $5.9M+151.5% |
| Retained Earnings | -$144.0Mn/m | -$92.0Mn/m | -$90.0Mn/m | -$88.0Mn/m | -$86.2Mn/m | -$84.2M | -$82.0Mn/m | -$79.9Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AZR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.4Mn/m | -$1.6Mn/m | -$1.3Mn/m | -$1.8Mn/m | -$1.7Mn/m | -$1.6Mn/m | -$1.5Mn/m | -$1.7Mn/m |
| Stock-Based Compensation | $137K+10.5% | $148K-37.5% | N/A | $147K-21.7% | $124K-38.7% | $237K+4.8% | N/A | $188K-29.9% |
| Investing Cash Flow | N/A | N/A | $0 | $0 | $0 | $150K | N/A | N/A |
| Financing Cash Flow | $25.2M+375.8% | $315K+522.5% | $2.6Mn/m | $525K-85.5% | $5.3M+1188.9% | $51K-98.7% | $0-100.0% | $3.6M+2503.6% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
AZR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26Filing | Q1'26Filing | Q4'25Filing | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -54.4%+50.4pp | -37.8%+13.1pp | -39.8%-2.6pp | -35.0%+22.4pp | -104.8%+1.0pp | -50.9%-3.9pp | -37.3%+22.0pp |
| Return on Assets | -178.7%-149.9pp | -38.7%+25.9pp | -29.9%+11.1pp | -31.7%+1.0pp | -28.8%+20.9pp | -64.6% | -41.0%-0.5pp | -32.6%+15.6pp |
| Current Ratio | 5.63+0.6x | 3.18+1.2x | 4.42+0.3x | 4.34-2.4x | 5.02-0.7x | 1.99 | 4.16-0.7x | 6.78+4.6x |
| Liabilities-to-Equity | N/A | 0.41-0.2x | 0.260.0x | 0.26+0.1x | 0.22+0.1x | 0.62 | 0.24+0.1x | 0.14-0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Azora Therapeutics, Inc. AZR | FY2025 | N/A | -$8.0M | N/A | $10.5M | — |
| Chemomab Therapeutics Ltd. CMMB | FY2025 | N/A | -$9.0M | N/A | $10.6M | — |
| CytoMed Therapeutics Limited GDTC | FY2025 | $252K | -$3.1M | N/A | $10.3M | — |
| IN8bio, Inc. INAB | FY2025 | N/A | -$19.4M | N/A | $10.0M | — |
| SeaStar Medical Holding Corporation ICU | FY2025 | $1.2M | -$12.2M | N/A | $10.0M | 53/100 |
| Psyence Biomedical Ltd. PBM | FY2026 | N/A | -$6.9M | N/A | $11.3M | — |
Where Azora Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Azora Therapeutics, Inc. (AZR) reported a net loss of $57.8M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $8.0M.
Azora Therapeutics, Inc. (AZR) has a return on equity of -151.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Azora Therapeutics, Inc. (AZR) recorded an outflow of $6.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Azora Therapeutics, Inc. (AZR) had $6.7M in total assets as of fiscal year 2025, including both current and long-term assets.
Azora Therapeutics, Inc. (AZR) invested $2.6M in research and development during fiscal year 2025.
Azora Therapeutics, Inc. (AZR) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.
Azora Therapeutics, Inc. (AZR) had a liabilities-to-equity ratio of 0.26 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Azora Therapeutics, Inc. (AZR) had a return on assets of -119.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Azora Therapeutics, Inc. (AZR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $10.5M as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Azora Therapeutics, Inc. (AZR) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $10.5M as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Azora Therapeutics, Inc. (AZR) held $5.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.5M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Azora Therapeutics, Inc. (AZR) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Azora Therapeutics, Inc. (AZR) reported a net loss of $8.0M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.